Canaccord analyst Shane Storey initiated coverage of Orthocell with a Speculative Buy rating and A$1.33 price target. The regenerative medicine company is commercializing novel collagen-based devices for peripheral nerve repair, including its flagship product, Remplir, the analyst tells investors. Recently achieved key global clearances, including FDA 510(k) clearance in April, position the company "at the start of a multi-year commercial expansion," the analyst added.
